Please login to the form below

Not currently logged in
Email:
Password:

outcomes

This page shows the latest outcomes news and features for those working in and with pharma, biotech and healthcare.

J&J’s Invokana first SGLT2 to show kidney disease benefits

J&J’s Invokana first SGLT2 to show kidney disease benefits

The trial puts Invokana one step ahead of rivals, such as AstraZeneca, the renal outcomes study for its SGLT2 drug Farxiga due in November 2020. ... Meanwhile Sanofi and Lexicon's Zynquista and Eli Lilly and Boehringer Ingeheim's market leader Jardiance

Latest news

More from news
Approximately 13 fully matching, plus 1,597 partially matching documents found.

Latest Intelligence

  • Breaking Bad Breaking Bad

    Satisficing vs satisfying. These two similar words have very different meanings and describe behaviours with very dissimilar outcomes. ... Compromise vs consensus. This is another pair of words that are often confused but which describe entirely

  • The first, my last, my everything The first, my last, my everything

    If you don’t engage your patients for the duration of your clinical trial, you’ll end up with poorer outcomes and a poorer reimbursement scenario. ... In the past, industry has taken a traditional view of patient value, typically basing it on

  • The Orkambi row explained The Orkambi row explained

    Obvious solutions include Vertex producing improved outcomes data for Orkambi (not likely, as it’s looking ahead to triple therapy) or a risk-sharing scheme, which it hasn’t been keen ... That leaves a compromise price cut, as part of the larger

  • Galderma launches Rosacea awareness campaign Galderma launches Rosacea awareness campaign

    As a leader in rosacea, Galderma is committed to gathering patient insights that enable us to tailor our approach to better support patient needs and help improve clinical outcomes in this

  • #OrkambiNow? #OrkambiNow?

    This would represent a transition towards an outcomes-based reimbursement system, which is certain to be central to market access for many novel drugs in the future.

More from intelligence
Approximately 10 fully matching, plus 391 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 61 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 5 fully matching, plus 413 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics